ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
LillyEli & Co

LillyEli & Co (LLY)

1.017,00
34,30
( 3,49% )
Aktualisiert: 16:21:20

LillyEli & Co (LLY) Aktie

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
1.017,00
( 3,49% )
Gebot
1.021,20
Fragen
1.022,20
Volumen
2.929
986,00 Tagesbereich 1.044,00
535,40 52-Wochen-Bereich 1.044,00
Marktkapitalisierung
Handelsende
982,70
Handelsbeginn
1.042,40
Letzte Trade
2
@
1017
Letzter Handelszeitpunkt
16:16:01
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
3.131.170 €
Ausgegebene Aktien
891.741.406
Dividendenrendite (LTM)
6,23 (0,72%)
Kurs-Gewinn-Verhältnis
40,19
Gewinn pro Aktie (EPS)
28,15
Erlöse (LTM)
72,25B
Nettogewinn (LTM)
25,28B

Über LillyEli & Co

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalo... Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer’s disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Website
Hauptsitz
Indianapolis, United States
Gegründet
1876
LillyEli & Co is listed in the Healthcare sector of the Tradegate (DE) with ticker LLY. The last closing price for LillyEli & was 982,70 €. Over the last year, LillyEli & shares have traded in a share price range of 535,40 € to 1.044,00 €.

LillyEli & currently has 891.741.406 shares in issue. The market capitalisation of LillyEli & is 906,90 € billion. LillyEli & has a price to earnings ratio (PE ratio) of 40.19.

LLY Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1747.847295864269431044903.92528949.44065343DE
4210.226.0535448686806.81044802.22366914.61200549DE
1215517.98143851518621044727.32394835.67066133DE
26148.917.152401797868.11044727.32614866.27656956DE
52341.350.5105816191675.71044535.43239759.1609981DE
156608.2148.776908023408.810449.68089994051713.69315292DE
260835.4460.022026432181.610449.68089992719665.31224763DE

LLY - Frequently Asked Questions (FAQ)

What is the current LillyEli & Co share price?
The current share price of LillyEli & Co is 1.017,00 €
How many LillyEli & Co shares are in issue?
LillyEli & Co has 891.741.406 shares in issue
What is the market cap of LillyEli & Co?
The market capitalisation of LillyEli & Co is EUR 906,9B
What is the 1 year trading range for LillyEli & Co share price?
LillyEli & Co has traded in the range of 535,40 € to 1.044,00 € during the past year
What is the PE ratio of LillyEli & Co?
The price to earnings ratio of LillyEli & Co is 40,19
What is the cash to sales ratio of LillyEli & Co?
The cash to sales ratio of LillyEli & Co is 13,96
What is the registered address of LillyEli & Co?
The registered address for LillyEli & Co is Lilly Corporate Center, Indianapolis, Indiana, 46285
What is the LillyEli & Co website address?
The website address for LillyEli & Co is www.lilly.com
Which industry sector does LillyEli & Co operate in?
LillyEli & Co operates in the Pharmaceuticals sector

LLY Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen